Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
WASHINGTON - The U.S. Food and Drug Administration (FDA) has authorized a range of nicotine pouches produced by Swedish Match, marking the first such approval for nicotine pouch products in the United States. The decision, which is aimed at providing adult smokers with alternatives to traditional tobacco products, encompasses all ZYN nicotine pouches currently marketed by the company in the U.S.
Swedish Match North America's president, Tom Hayes, commented on the FDA's decision, stating that it acknowledges ZYN's potential role in public health by offering a substitute for cigarettes and other conventional tobacco products for adults over the age of 21.
The FDA authorized the following products:
ZYN Cool Mint 3 mg
ZYN Cool Mint 6 mg
ZYN Peppermint 3 mg
ZYN Peppermint 6 mg
ZYN Spearmint 3 mg
ZYN Spearmint 6 mg
ZYN Wintergreen 3 mg
ZYN Wintergreen 6 mg
ZYN Citrus 3 mg
ZYN Citrus 6 mg
ZYN Coffee 3 mg
ZYN Coffee 6 mg
ZYN Cinnamon 3 mg
ZYN Cinnamon 6 mg
ZYN Smooth 3 mg
ZYN Smooth 6 mg
ZYN Chill 3 mg
ZYN Chill 6 mg
ZYN Menthol 3 mg
ZYN Menthol 6 mg
The FDA's approval is seen as a significant step towards addressing the needs of the estimated 45 million Americans who regularly consume nicotine, of which approximately 30 million are smokers. Smoking is widely recognized as the most harmful method of nicotine consumption.
Swedish Match North America, a subsidiary of Philip Morris International Inc. (NYSE:PM), has emphasized its commitment to marketing practices that support access exclusively for individuals 21 years of age and older.
The move by the FDA is part of ongoing efforts to regulate nicotine delivery products and reduce the health risks associated with smoking. As the first and only authorized nicotine pouch in the U.S., ZYN may contribute to the broader goal of harm reduction in tobacco use.
This article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.